Ambion, Rosetta, Alnylam, Stanford University, Galapagos, Invitrogen, Hutchinson Cancer Center | GenomeWeb

Ambion Licenses microRNA Sequences from Rosetta Genomics

Rosetta Genomics and Ambion have signed an agreement that will give Ambion access to Rosetta's proprietary microRNA sequences, the companies said this week.

Under the terms of the agreement, Ambion will adapt its platform to detect, quantify, and characterize proprietary microRNA sequences discovered by Rosetta, a developer of microRNA-based therapeutics and diagnostics.

Additional terms of the agreement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.